APM
ABUS icon

Avidity Partners Management’s Arbutus Biopharma ABUS Stock Holding History

Avidity Partners Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-125,000
Closed -$563K – 46
2026
Q1 		$563K Buy
+125,000
New +$547K 0.11% 42

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Avidity Partners Management's ABUS Position: Q2 2026 in Review

Avidity Partners Management sold out of Arbutus Biopharma (ABUS) in Q2 2026, closing a stake of 125,000 shares — an estimated $563K sold.

Avidity Partners Management first reported a position in ABUS in Q1 2026 and held it in 1 quarter. The position peaked at $563K in Q1 2026. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Avidity Partners Management reported no remaining Arbutus Biopharma position as of Q2 2026 after selling out during the quarter.
  • Avidity Partners Management sold 125,000 Arbutus Biopharma shares in Q2 2026, an estimated $563K.
  • Avidity Partners Management first reported a position in Arbutus Biopharma in Q1 2026 and held it in 1 quarter.
  • Avidity Partners Management's Arbutus Biopharma position peaked at $563K in Q1 2026.
  • 176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Avidity Partners Management's 13F filing for Q2 2026, filed 14 Aug 2026.